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Astrocyte reactivation has been discovered to be an important contributor to several neurological 
diseases. In vitro models involving human astrocytes have the potential to reveal disease-specific 
mechanisms of these cells and to advance research on neuropathological conditions. Here, we induced 
a reactive phenotype in human induced pluripotent stem cell (hiPSC)-derived astrocytes and studied 
the inflammatory natures and effects of these cells on human neurons. Astrocytes responded to 
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) treatment with a typical transition to 
polygonal morphology and a shift to an inflammatory phenotype characterized by altered gene and 
protein expression profiles. Astrocyte-secreted factors did not exert neurotoxic effects, whereas 
they transiently promoted the functional activity of neurons. Importantly, we engineered a novel 
microfluidic platform designed for investigating interactions between neuronal axons and reactive 
astrocytes that also enables the implementation of a controlled inflammatory environment. In 
this platform, selective stimulation of astrocytes resulted in an inflammatory niche that sustained 
axonal growth, further suggesting that treatment induces a reactive astrocyte phenotype with 
neurosupportive characteristics. Our findings show that hiPSC-derived astrocytes are suitable for 
modeling astrogliosis, and the developed in vitro platform provides promising novel tools for studying 
neuron-astrocyte crosstalk and human brain disease in a dish.
Astrocytes are the most abundant cell type in the central nervous system (CNS) and play important roles in 
supporting neuronal cell functions by releasing energy substrates and trophic factors, maintaining homeostatic 
functions and regulating neuronal synaptogenesis and synaptic transmission1–4. During CNS injury and disease, 
astrocytes transform into a reactive phenotype with changed morphology and altered gene expression and secre-
tion profiles4,5. These astrocytes are regarded as immunocompetent cells that can respond to complex inflamma-
tory events by secreting cytokines and chemokines, thereby controlling immune cell activation and migration 
to sites of damage5,6. Astrocytes are considered to play a dual role in CNS pathophysiology, as they can both 
support regeneration and exert detrimental effects on surrounding cells and brain parenchyma6,7. Interestingly, 
two distinct astrocyte phenotypes were recently described in rodent studies: a detrimental A1 type and a benefi-
cial A2 type8,9. Of these, A2 astrocytes were associated with ischemia-induced CNS lesions, while A1 astrocytes 
dominated in inflammation-induced lesions reflecting those in diseases such as multiple sclerosis (MS). However, 
reactivation of astrocytes is a complex phenomenon that possibly results in a mixture of the two phenotypes or 
even several distinct yet unidentified activation states10.
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The majority of the knowledge on reactive astrocytes has been gathered from rodent studies, whereas the 
inflammatory nature of human astrocytes has received less attention9–11. Nevertheless, growing evidence shows 
significant structural and functional differences between human and rodent astrocytes, underlining the relevance 
of further studies focusing on human astrocytes and their behaviors12–14. In vitro studies with human cells have 
typically utilized astrocytes from primary fetal or adult tissues or immortalized astrocytoma cell lines14–17; how-
ever, the availability of human primary astrocytes is limited, and immortalized cells are often criticized as model 
systems. Advancements in the field of stem cell biology have enabled the differentiation of astrocytes from human 
pluripotent stem cells (hPSCs)18–22, providing an unlimited cell source and an option to create disease-specific 
cell lines. Despite these advancements, only a few studies have described the reactivation of hPSC-derived astro-
cytes18,22–25, and even fewer studies have reported the interplay of inflammation or reactive astrocytes with human 
neuronal cells24,26,27.
The development of newly engineered in vitro platforms based on hPSC-derived cells is a promising approach 
for studying the mechanisms of CNS functions and disorders28–30. Microfluidic devices are potent research tools 
for studying the interactions of several cell types in controlled, compartmentalized culture environments31,32. For 
example, multiple cell compartments can be connected via microtunnels, allowing the growth of axons while 
restricting neuronal somas thus facilitating experimentation on cellular processes and cell-to-cell interactions31. 
Advantages in microfluidic technology have already been validated, for instance, in axonal transport and mye-
lination studies33–39. However, less data are available on neuron-astrocyte interactions and neuroinflammatory 
activity26,31. Understanding the complex cellular interplay among several neural cell types can help to reveal 
underlying mechanisms in neurodegenerative diseases and create opportunities for drug discovery.
Here, we studied reactivation using human induced pluripotent stem cell (hiPSC) -derived astrocytes and 
observed their transformation into cells with reactive proinflammatory phenotypes with neurosupportive char-
acteristics. Furthermore, we designed a novel microfluidic co-culture platform including neurons, astrocytes and 
an inflammatory environment that was validated for studying reactive astrocyte-neuron interactions. We are 
convinced that hiPSC-astrocyte model systems can facilitate investigation of specific human cell properties and 
ultimately model human CNS diseases in a dish.
Results
Characterization of hiPSC-derived astrocytes. HiPSC-derived astrocytes were first characterized in 
their quiescent resting state for the expression of astrocyte-specific markers at the gene and protein levels. Gene 
expression analysis revealed expression of transcripts typical for developing astrocytes, including S100 calci-
um-binding protein beta (S100β) and vimentin (VIM) (Fig. 1a). Additionally, mature astrocyte genes, such as 
glial fibrillary acidic protein (GFAP) and excitatory amino acid transporters 1 and 2 (EAAT1 and EAAT2, respec-
tively), were expressed (Fig. 1a). Major astrocyte-specific markers were also confirmed by immunocytochemi-
cal staining of GFAP, S100β, glutamine synthetase (GS), aldehyde dehydrogenase 1 family member (Aldh1L1), 
EAAT1 and EAAT2 (Fig. 1b). To confirm that the astrocytes were mostly negative for neuronal markers, the cells 
were stained for microtubule-associated protein 2 (MAP2) (Supplementary Fig. S1). Thus, the culture consisted 
of a heterogeneous astrocyte population with a cell type-specific expression signature.
Treatment of hiPSC-derived astrocytes with IL-1β and tnf-α induces a reactive phenotype. 
To induce a reactive astrocyte phenotype with inflammatory cytokines and to characterize astrocyte properties, 
an extended seven-day co-stimulation with IL-1β and TNF-α was performed (Fig. 2a). First, the presence of 
cytokine receptors for IL-1β and TNF-α in hiPSC-derived astrocytes was analyzed in the quiescent resting state. 
The expression of IL-1 receptor 1 (IL1R) and IL-1 receptor accessory protein (IL1RAP), as well as that of tumor 
necrosis factor receptor superfamily 1 A (TNFRSF1A), which is important for mediating the signals of these 
Figure 1. Characterization of hiPSC-derived astrocytes. (a) The hiPSC-derived astrocytes expressed 
several astrocyte-specific genes, including GFAP, VIM, S100B, EAAT1 and EAAT2. The data are presented 
as the mean ± s.e.m. (n = 2 with three technical replicates; the data are representative of two experiments). 
(b) Immunocytochemical staining was used to confirm the expression of the major astrocyte markers GFAP, 
S100β, GS, Aldh1L1, EAAT1 and EAAT2.
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Figure 2. IL-1β and TNF-α treatment induces a reactive astrocyte phenotype. (a) Experimental setup for 
astrocyte stimulation with IL-1β and TNF-α and astrocyte characterization. (b) Gene expression analysis 
revealed the presence of TNFRSF1A, IL1R, and IL1RAP transcripts in the astrocytes (n = 2 with three technical 
replicates; the data are representative of two experiments). (c) In control astrocytes, NF-κB was ubiquitously 
expressed in the cytoplasm, whereas after 60 minutes cytokine stimulation, it was activated and translocated to 
the nucleus (white arrows). (d) NF-κB activation was quantified as the percentage of nuclei with translocation 
among the total nuclei (n = 6 cultures; the data were analyzed from two experiments). (e) Immunocytochemical 
staining of the intermediate filament proteins vimentin and GFAP showed morphological changes from 
filamentous to flattened shapes (white arrows) in response to cytokine stimulation. (f) Morphological change 
was quantified based on the vimentin staining of samples on day 7. The circularity of the cells in each group 
is presented as the median and interquartile range, with the whiskers showing the minimum and maximum 
values. Images were analyzed from six cultures derived from three experiments. (g) GFAP expression levels 
decreased following cytokine stimulation (n = 2 with three technical replicates; the data are representative of 
two experiments). (h) GFAP was analyzed at the protein level by western blot analysis, representative cropped 
images of the membranes for the GFAP and β-Actin are shown here and full length of membranes are presented 
in the Supplementary Fig. S4. (i) Quantification of GFAP and β-Actin showed a reduction after cytokine 
treatment. β-Actin was used as a loading control (n = 2; the data are representative of three experiments). 
(j) Cytokine treatment impaired the glutamate uptake capacity of astrocytes (n = 3; the data are representative 
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cytokines, was confirmed (Fig. 2b). However, TNFRSF1B was not detectable in the hiPSC-derived astrocytes 
(Fig. 2b).
Nuclear factor kappa B (NF-κB) is a key transcription factor that has been shown to be activated in reac-
tive astrocytes during neuroinflammation6. Here, NF-κB was ubiquitously present in the cytoplasm of quiescent 
astrocytes but was only present in low amounts in the nuclei (Fig. 2c). However, soon after the initiation of 
cytokine treatment, NF-κB was activated and translocated to the nucleus (Fig. 2c, Supplementary Fig. S2). After 
60 min of cytokine stimulation, a significant portion (over 50%) of the astrocytes showed activation of the NF-κB 
pathway (control [Ctrl] 9.7 ± 0.6 vs. IL-1β/TNF-α treated [Trt] 55.3 ± 1.9, p < 0.001, Fig. 2d).
Reactive astrocytes undergo changes in morphology typically characterized by hypertrophy of main cellu-
lar processes40. Over the 7-day cytokine treatment period, the astrocytes gradually exhibited a morphological 
change from a highly filamentous shape to a flattened polygonal appearance (Supplementary Fig. S3). This typical 
response was most notable upon the staining of the intermediate filament proteins vimentin and GFAP, both 
of which contribute to astrocyte morphology (Fig. 2e). The morphology of the control and treated astrocytes 
was quantified based on vimentin staining at the 7-day time point (Fig. 2f). The circularity index was calculated 
according to the area and perimeter metrics of each cell, with a value of 1 describing a perfectly circular object. 
Quantification confirmed that the astrocytes lost their filamentous shape and adopted a more circular morphol-
ogy in response to cytokine activation (medians Ctrl 0.16 vs. Trt 0.27, p < 0.001, Fig. 2f).
Changes in intermediate filament protein expression have often been considered to be hallmarks of reactive 
astrocytes10. Although the cytokine-stimulated reactive astrocytes showed positive staining for GFAP (Fig. 2e), 
we observed an 8-fold decrease in mRNA levels after the 7-day treatment in the treated cells compared to the 
controls (Ctrl 8.81 ± 0.54 vs. Trt 1.05 ± 0.15, p < 0.001, Fig. 2g). The GFAP protein levels were also confirmed by 
western blot analysis, showing similar decreases as a result of IL-1β and TNF-α treatment (Ctrl 0.73 ± 0.04 vs. Trt 
0.16 ± 0.06, p = 0.010, Fig. 2h–i, Supplementary Fig. S4). Additionally, the vimentin protein levels were studied 
and were found to remain more stable than GFAP protein levels after cytokine treatment (Supplementary Fig. S4).
Uptake of glutamate from the extracellular space is an important function of astrocytes that sustains healthy 
synaptic transmission of neurons4. Impairment in the uptake of glutamate from the culture medium was revealed 
in cytokine-stimulated astrocytes compared to control astrocytes (Ctrl 42.4 ± 1.4 vs. Trt 9.0 ± 0.66, p < 0.001, 
Fig. 2j). In summary, treatment with the cytokines IL-1β and TNF-α activated astrocytes, modified their inter-
mediate filament cytoskeleton and transformed them morphologically and functionally into cells with a reactive 
phenotype.
Cytokine treatment induces astrocyte proliferation and reduces viability. Next, we stud-
ied the effects of cytokines on the viability and proliferation of astrocytes after a 7-day treatment regimen. 
Immunocytochemical staining with the proliferation marker Ki67 showed a slight (5%) but significant increase in 
proliferation in cytokine-treated cells compared to control cells (Ctrl 6.8 ± 0.9 vs. Trt 11.8 ± 0.7, p < 0.001, Fig. 3a–
b). However, this increase did not significantly affect the total nuclei count (Ctrl 1094 ± 28 vs. Trt 1040 ± 55, 
Fig. 3c) or the total DNA amount (Ctrl 95476.7 ± 8299.5 vs. Trt 89263.8 ± 8779.2, Fig. 3d). Upon assessing the 
viability of astrocytes after cytokine treatment, a significant increase in cytotoxicity (Ctrl 1053.0 ± 55.8 vs. Trt 
2677.3 ± 461.2, p = 0.017) and a decrease in viability (Ctrl 38938.2 ± 2347.3 vs. Trt 17999.2 ± 3352.4, p < 0.001) 
in the treated cells compared to the control cells were found (Fig. 3e). In the apoptosis metrics, no statistically sig-
nificant differences were detected between the groups (Ctrl 26026.8 ± 4362.3 vs. Trt 20265.8 ± 3629.6, Fig. 3e). In 
conclusion, cytokine treatment of hiPSC-derived astrocytes caused minor proliferation, but the total cell number 
remained stable due to cytotoxicity.
Reactivation induces a proinflammatory response in astrocytes. To reveal whether the astrocytes 
were able to produce an immune response, the gene expression and secretion profiles of inflammatory markers 
were characterized. First, the effects of IL-1β and TNF-α treatment on the expression of the inflammation-related 
genes CCL5, CXCL8, complement component 3 (C3) and lipocalin-2 (LCN2) were studied (Fig. 4a–d). At the 
basal level, none of the transcripts were expressed, whereas treatment for 24 h led to over 300-fold increases in 
the expression of the chemokines CCL5 and CXCL8 (Fig. 4a–b). Recently, C3 has been linked to astrocyte reac-
tivity8,41. Here, C3 expression increased in a time-dependent manner after cytokine treatment, reaching over a 
200-fold change compared to the control level at the 7-day time point (Fig. 4c). The gene expression of LCN2 also 
considerably increased over 7 days, although the change was not as prominent as that for the other transcripts 
(Fig. 4d).
Next, the secretion of 105 inflammatory proteins (see full list in Supplementary Table  1) from 
cytokine-stimulated astrocytes was studied (Fig. 4e; Supplementary Fig. S5a). Treatment induced widespread 
protein secretion at the 24 h and 7-day time points (Fig. 4e and Supplementary Fig. S4a). The most highly secreted 
proteins were chemokines (CXCL10, CXCL5, CXCL8, CCL2, CXCL1, and CCL5), but other inflammatory fac-
tors, such as pentraxin 3 (PTX3), osteopontin (OPN), chitinase-3 like 1 (CHI3L1), Serpin E1 and adhesion mol-
ecule vascular cell adhesion protein-1 (VCAM1), were also secreted. Among the cytokines, IL-6, IL-1β, TNF-α 
and macrophage migration inhibitory factor (MIF) were detected on medium obtained from the cytokine-treated 
astrocytes.
of two experiments). The data are presented as the mean ± s.e.m. Statistical analysis was performed with 
independent-sample t-tests except in (f), in which statistical analysis was performed with the Mann-Whitney U 
test. Statistical significance: * p < 0.05, ** p < 0.01, and *** p < 0.001.
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IL-6 is a classic inflammatory mediator known to be secreted from astrocytes after reactivation42; therefore, 
the secretion of IL-6 was further investigated. Control astrocytes did not secrete IL-6, but cytokine-stimulated 
astrocytes gradually secreted IL-6, the levels of which reached 2000 pg/ml at the 7-day time point (Fig. 4f). In 
summary, astrocytes responded to cytokine treatment with changes in gene expression and broad secretion of 
proinflammatory factors.
Astrocyte conditioned medium sustains neuronal viability and supports functional activ-
ity. Astrocyte activation resulted in widespread secretion of inflammatory molecules; therefore, we next 
studied whether astrocyte conditioned medium (ACM) has an effect on neurons. Astrocytes were treated with 
IL-1β and TNF-α for seven days; the treatment was then washed out, and the ACM was collected 48 h later. 
At this stage, the astrocytes still secreted a broad profile of inflammatory factors (Supplementary Fig. S5b). 
In-house-differentiated hPSC-derived neurons were exposed to ACM for 48 h, after which they still retained 
a normal branched neuronal morphology (Fig. 5a). Additionally, ACM treatment did not cause any changes 
in viability or apoptosis or cause cytotoxicity, confirming that the produced reactive astrocytes did not secrete 
neurotoxic factors at detrimental levels (Fig. 5b). Similar results were obtained with commercial hiPSC-derived 
neurons (Supplementary Fig. S6a–b).
The effect of ACM on neuronal functionality was studied with a microelectrode array (MEA) setup, which 
allowed repeated measurements from the same network. In-house-differentiated hPSC-derived neuronal cells 
were first cultured on MEAs for five weeks until mature bursting and synchronic activity was achieved through-
out the network (Fig. 5c–d). Once array-wide activity had developed, the cultures were treated with control ACM 
or reactive ACM, and measurements were performed immediately (acute) and at 1 h, 4 h and 24 h after ACM 
application (Fig. 5e). A naïve control group received the same volume of intact medium (held for 48 h in an incu-
bator similar to that in which the collected ACM was held). Overall, addition of the media induced increases in 
spike rates in all studied groups and, to a lesser extent, increases in burst counts during the 24 h follow-up period 
(Fig. 5e–f, Supplementary Table 2). The magnitudes of these changes were not as great in the commercial neurons 
as in the in-house-differentiated neurons (Supplementary Fig. S6d–e).
Next, activity changes in relation to baseline measurements were studied between the different treatment 
groups (Fig. 5g–h). The control ACM- and reactive ACM-treated networks responded similarly, as no significant 
Figure 3. Viability and proliferation of cytokine-treated astrocytes. (a) Immunocytochemical staining of 
proliferating Ki67-positive cells in control and IL-1β/TNF-α-treated cultures. (b) The number of proliferating 
cells was increased after cytokine treatment. (c) The nuclei count quantified from DAPI staining remained 
similar between the control and treated groups. For Ki67 staining and nuclei counts, images were analyzed 
from 11 cultures derived from four experiments. (d) Additionally, the amount of DNA was similar between the 
groups (n = 6 with two technical replicates; the data are from two experiments). (e) The viability assay showed 
decreased viability and increased cytotoxicity but no significant difference in apoptosis following cytokine 
treatment (n = 3; the data are representative from two experiments). The quantification data are presented as the 
mean ± s.e.m. All statistical analysis was performed using independent-sample t-tests. The significant p-values 
are presented in the graphs. Statistical significance: * p < 0.05, ** p < 0.01, and *** p < 0.001.
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differences between them were detected in spike or burst rates (Fig. 5g–h). This result was confirmed with both 
in-house-produced (Fig. 5g–h) and commercial neurons (Supplementary Fig. S6f–g).
In comparison to the control group, the reactive ACM group demonstrated an immediate increase in spike 
activity (Ctrl -0.168 ± 0.039 vs. reactive ACM 0.025 ± 0.036, p = 0.033) and a decrease in activity at the 24 h time 
point (Ctrl 0.470 ± 0.066 vs. reactive ACM 0.250 ± 0.087, p = 0.045, Fig. 5g–h). However, the control ACM group 
exhibited both increased spike activity (Ctrl 0.349 ± 0.067 vs. Ctrl ACM 0.576 ± 0.095, p = 0.039) and increased 
burst rate (Ctrl 0.579 ± 0.377 vs. Ctrl ACM 2.048 ± 0.535, p = 0.02) at the 1 h time point compared to the control 
group. Similar changes in spike and burst rates were also confirmed with commercial neurons (Supplementary 
Fig. S6f–g). Thus, conditioned medium from reactive astrocytes did not cause any detectable cytotoxicity or 
functional silencing of neuronal networks. In fact, both control and reactive ACM supported functional activity, 
suggesting that astrocytes were neurosupportive rather than neurotoxic under these conditions.
Generation of a controlled astrocyte-neuron co-culture system utilizing a microfluidic 
device. Next, we established a novel platform enabling controlled co-culture of neurons and astrocytes, 
targeted stimulation of astrocytes, and study of neuron-astrocyte interactions (Fig. 6a). The microfluidic 
device is composed of separate compartments for neurons and astrocytes, which are connected via micro-
tunnels and axonal compartment (Fig. 6a,b, Supplementary Fig. S7). Immunofluorescence staining demon-
strated that β-tubulin-positive neuronal somas were restricted to their designated compartments (Fig. 6c–e), 
while NF-H-positive axons grew readily through the microtunnels into the axonal compartment (Fig. 6d). 
GFAP-positive astrocytes were restricted to the astrocyte compartment (Fig. 6c), and direct cell-to-cell inter-
actions could be verified, as astrocyte processes extended through the microtunnels and connected to neuronal 
axons in the neighboring compartment (Fig. 6e,f).
Figure 4. Cytokine treatment results in the inflammatory activation of astrocytes. (a–d) The gene expression 
levels of (a) CCL5, (b) CXCL8, (c) C3, and (d) LCN2 were analyzed in cytokine-treated and control astrocytes 
at the 0-, 1-, 3- and 7-day time points. Robust increases in the expression of all studied genes were detected 
after cytokine treatment (n = 2 with three technical replicates; the data are representative of two experiments). 
(e) Secretion of inflammatory factors into the medium was analyzed at the 24 h and 7-day time points. The 
relative intensity values for the different analytes were calculated by subtracting the intensity values of the 
control samples from those of the cytokine-treated samples at each time point (n = 1 with two technical 
replicates; the data are representative of two experiments). (f) The levels of IL-6 were analyzed at 0, 1, 3 and 7 
day in cytokine-treated and control astrocytes. IL-6 levels increased in a time-dependent manner over 7 days 
in the cytokine-treated samples, while under control conditions, the levels were undetectable (n = 2 with two 
technical replicates; the data are representative of two experiments). The quantification data are presented as the 
mean ± s.e.m.
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Figure 5. Viability and functionality of neuronal cells after exposure to reactive astrocyte conditioned medium. 
(a) Immunocytochemical staining of hPSC-derived neuronal cells exposed to control medium (Ctrl), control 
ACM (Ctrl ACM) and reactive ACM. Neuronal cells stained positive for MAP2 (green) and β-tubulin (red). 
DAPI nuclear staining is shown in blue. (b) The reactive astrocyte conditioned medium did not show an effect 
on the viability, cytotoxicity or apoptosis of neuronal cells after 48 h of exposure (the data are representative of 
two experiments; in each experiment n = 3–6 per group). Statistical analysis was performed using independent-
sample t-tests. (c) The effect of ACM on neuronal functionality was studied with microelectrode array (MEA) 
measurements. The phase-contrast images show neuronal cells cultured on MEAs. (d) Typical spontaneous 
activity in neuronal networks recorded from three electrodes over 5 minutes. The raster blot shows the typical 
network-wide activity from all 16 electrodes of one well over 5 minutes. (e) Spike rate (Hz) development for 
active electrodes before (baseline) and after different medium exposures (acute, 1 h, 4 h and 24 h). (f) Number 
of bursts per minute before and after different medium exposures. For the MEA data, n = 12 networks derived 
from one differentiation. The data are presented as the mean ± s.e.m., and statistical analysis was performed 
using the Friedman test. (g-h) To highlight significant differences between treatment groups, the data from 
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Fluidic isolation of the astrocyte compartment from the neuron compartment was demonstrated with 
FITC-conjugated dextran particles, which did not diffuse to the neuron compartment, as detected by fluorescence 
imaging (Fig. 6g) and measurements of particle concentrations after 24 h (Fig. 6h). However, over 24 h, particles 
did diffuse from the astrocyte compartment into the axonal compartment, verifying the possibility of studying 
humoral effects on axons with this system (Fig. 6g). In summary, the generated platform enabled the isolation of 
different cell types and cell parts, and the control of cell-to-cell interactions and fluid flow.
Reactive astrocytes and an inflammatory environment affect axonal growth in the microfluidic 
platform. The last aim was to induce the reactive astrocyte phenotype in the microfluidic platform and study 
the effect of reactive astrocytes on axon growth in the axonal compartment (Fig. 7a). To treat astrocytes, IL-1β 
and TNF-α were applied to the astrocyte compartment after the neurons and astrocytes were both plated into 
the microfluidic platform (Fig. 7a). The 72 h cytokine treatment did not cause any major cytotoxic effects on 
either cell type, as only a few dead cells were detected among viable cells (Fig. 7b). Similar to the findings under 
open-well conditions described above, the reactive astrocytes secreted a wide range of inflammatory factors (e.g., 
VCAM1, CCL2, CXCL8, CXCL5, and CHI3L1) (Fig. 7c, Supplementary Fig. S8).
After confirming the proinflammatory phenotype of the astrocytes, the effect of these astrocytes on axonal 
growth was studied by quantifying the number and density of axons extending to the axonal compartment 
(Fig. 7d–g). In addition to devices with co-cultures of control or reactive astrocytes with neurons (treatment 
groups: Neu + Ctrl astro and Neu + Reactive astro), devices with only neurons were included in the study to 
elucidate whether treatment with IL-1β and TNF-α alone had an effect on axons (treatment groups: Neu and 
Neu + IL-1β/TNF-α). Over the 72 h follow-up period, no statistically significant differences were detected in axon 
counts between the groups (Fig. 7e). Furthermore, axonal density was assessed with live-cell calcein-AM color 
staining by quantifying the area coverage in the axonal compartment 72 h after cytokine treatment (Fig. 7f,g). The 
results showed that reactive astrocytes increased axonal density compared to control astrocytes (Neu + Ctrl astro 
4.7 ± 0.6 vs. Neu + Reactive astro 8.2 ± 1.3, p = 0.028, Fig. 7g). Taken together, the results indicate that selective 
cytokine stimulation of astrocytes resulted in an inflammatory environment that had a positive effect on axonal 
growth, demonstrating the suitability of the developed cell model for studying axonal biology.
Discussion
Astrocytes are an acknowledged partner in the inflammatory processes in many neurodegenerative diseases and 
injuries of the CNS5,11. Astrocytes regulate the homeostasis of their surroundings and can have direct effects on 
neurons, both beneficial and detrimental. Human astrocytes are known for their complexity and heterogeneity, 
and some of their structural and functional traits differ from those of rodent astrocytes12–14. Therefore, in this 
study, we used hiPSC-derived astrocytes to create a human cell model system to study the inflammatory activa-
tion of astrocytes and the effects of activated astrocytes on neuronal functionality and axonal growth.
A variety of inflammatory molecules have been studied for their ability to induce a reactive astrocyte pheno-
type in vitro8,23,43. Here, astrocytes were treated with a combination of the cytokines IL-1β and TNF-α, which are 
typically released by activated microglia during neuroinflammation and are capable of stimulating astrogliosis 
in vivo5,44,45 and in vitro18,46–48. Furthermore, co-stimulation with IL-1β and TNF-α has been demonstrated to 
be a more potent trigger of reactivity that stimulation with either of the cytokines independently8,23. To date, few 
reports have described the responses of hiPSC-derived astrocytes to cytokine treatments18,22–25,41. However, many 
astrocyte differentiation protocols use serum to enhance astrocytes production that can promote astrocyte reac-
tivation14,23. Here, astrocytes were cultured in serum-free medium, and under control conditions, the astrocytes 
remained in a quiescent state according to the results of gene expression and secretion profile analysis. We also 
treated astrocytes with the inflammatory cytokines for 7 days as described previously18 to mimic chronic effects. 
During the 7-day activation, we observed a gradual change in the morphology of the astrocytes from fibrous to 
polygonal and a reorganization of intermediate filament proteins, which are typical hallmarks of astrogliosis in 
vivo6. This clear morphological change has previously been demonstrated in vitro with human fetal astrocytes14,46 
but not reported with hiPSC-derived astrocytes18,22,25. Additionally, upregulation of GFAP has been commonly 
described in relation to astrogliosis in vivo10. Interestingly, even though both control and reactive astrocytes 
stained positive for GFAP, more detailed analysis revealed downregulation of GFAP at both the gene and total 
protein levels upon cytokine treatment. Consistent with our data, reductions in GFAP have been reported in 
IL-1-treated human fetal astrocytes49 and in IL-1β- and TNF-α-treated rodent astrocytes at both the gene and 
protein levels8,43. Overall, we showed morphological transformation and alterations in the structural proteins of 
reactive astrocytes following 7-day IL-1β and TNF-α treatment.
Astrocytes are immunocompetent cells, and inflammatory activity upon stimulation is therefore their impor-
tant feature6. The key signaling pathways involved in astrocyte reactivation include NF-κB pathway, which was 
acutely activated after cytokine treatment in the present study. NF-κB activation is known to induce the pro-
duction of proinflammatory cytokines, chemokines and adhesion molecules, which mediate leukocyte recruit-
ment to the CNS, leading to neuroinflammation7,10,50. Here, we demonstrated the secretion of a wide variety of 
chemokines, cytokines and other inflammatory factors by reactive astrocytes. For example, secretion of the typ-
ical inflammatory markers CCL5, CXCL8 and IL-6 was temporally induced after cytokine treatment, which has 
also been previously reported in studies on IL-1β- and TNF-α-treated hiPSC-derived astrocytes18,22. Interestingly, 
panels e-f were reused and are presented as the changes in spike and burst rates compared to the baseline 
measurements. The data are shown as Tukey boxplots. Statistical significances was determined with the Mann-
Whitney U test; * p < 0.05, ** p < 0.01, and *** p < 0.001.
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we observed upregulation of complement component 3 (C3), which has been linked to the neuroinflammatory 
phenotype of reactive astrocytes and has also been detected in demyelinating lesions of MS patients8,9. For the first 
time, we detected CHI3L1, OPN, and PTX3, known astrogliosis-associated markers in vivo9, in hiPSC-derived 
reactive astrocytes; these proteins are also considered candidate diagnostic and prognostic biomarkers for CNS 
diseases51,52. Thus, a broad range of inflammatory factors were discovered in a human model system of astroglio-
sis; however, the specific roles of these factors in neuroinflammatory processes remain to be explained.
Only a handful of studies have addressed interactions between reactive astrocytes and neurons in vitro using 
human cells8,24,26,53. Here, humoral signaling by reactive astrocytes sustained neuronal viability, suggesting 
that the astrocyte secretion profile was not primarily neurotoxic. In contrast, previous studies have described 
decreased numbers of neurons in direct co-cultures of human neurons and IL-1β-stimulated astrocytes24, and the 
humoral effects of TNF-α, IL-1α and complement component 1q (C1q) -stimulated rodent astrocytes have been 
reported to be toxic to human neurons8. Here, responses were also studied on a more sensitive neuronal network 
functionality level54. ACM exposure did not silence neuronal network activity but rather supported function-
ality, suggesting the polarization of astrocytes into a neurosupportive state. Previous studies have shown that 
secreted factors as well as direct cell-to-cell contact with rodent astrocytes can increase the activity of networks 
Figure 6. Description of the microfluidic device for co-culture of neurons and astrocytes and the 
fluidic isolation of the cell compartments. (a) Schematic showing a 3D illustration of the microfluidic 
device. (b) The microfluidic device consisted of two opposing compartments for neurons and a separate 
compartment for astrocytes, all of which were connected to an axonal compartment via microtunnels. 
(c) Immunocytochemical staining showing successful co-culture of β-tubulin-positive neurons and GFAP- 
and vimentin-positive astrocytes in the device and (d) the presence of NF-H-positive axons growing into the 
axonal compartment. (e) GFAP-positive astrocytes were placed close to the microtunnels leading to the axonal 
compartment, and (f) enlargement of the image illustrates cell-to-cell interactions between astrocytic processes 
and axons. (g) To evaluate the fluidic isolation of the astrocyte compartment, dextran-conjugated FITC was 
added to the astrocyte compartment, and its diffusion was evaluated by imaging with fluorescence microscopy 
at 1 h and 24 h. Fluorescence was detected in the axonal compartment after 24 h but was absent in the neuronal 
compartment (the compartments are shown with white dotted lines). (h) The concentration of dextran-FITC 
was measured after 24 h from medium collected from the astrocyte and neuron compartments. The data are 
shown as the mean ± s.e.m. (n = 6; the data are from one experiment). Statistical analysis was performed with 
independent-sample t-tests, and statistical significance is denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001.
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Figure 7. In vitro model for astrogliosis and axonal growth. (a) Experimental design for co-culture of astrocytes 
and neurons in the microfluidic device and astrocyte activation with IL-1β and TNF-α. (b) Both cell types 
remained viable (based on calcein-AM staining) on the platform after cytokine treatment, and very few dead 
cells (revealed by EtHD-1 staining) were observed. (c) Cytokine-treated astrocytes secreted significantly 
higher levels of several inflammatory factors than controls (n = 2; the data are from one experiment). (d) Phase-
contrast images showing axons extending into the axonal compartment at 0 h and 72 h after cytokine treatment. 
(e) The number of axons extending into the axonal compartment (crossing the distance marked with the white 
dotted line) was quantified over 72 h. In addition to devices with co-cultures of control or reactive astrocytes 
and neurons (the Neu + Ctrl astro and Neu + Reactive astro groups), devices with cultures of only neurons were 
established to determine the effects of IL-1β and TNF-α treatment on axons (the Neu and Neu + IL-1β/TNF-α 
group) (n = 4–8 for each group; the data are from two experiments). (f) Axonal growth was also visualized with 
live-cell calcein-AM color staining to estimate coverage in the axonal compartment (the white dotted line). 
(g) Quantification of the area coverage in the axonal compartment revealed that reactive astrocytes supported 
axonal growth compared to control astrocytes (n = 6–13 for each group; the data are from one independent 
experiment). All data are presented as the mean ± s.e.m. Statistical analysis between groups was performed with 
independent-sample t-tests. P-values less than 0.05 were considered to indicate significance, and significant 
differences compared to the control group are presented in the graphs as * p < 0.05, ** p < 0.01, and *** p < 0.001.
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on MEAs55,56. On the other hand, neurotoxic astrocytes have failed to promote synapse function8. Altogether, 
our results suggest that 7-day stimulation of hiPSC-derived astrocytes with cytokines results in an inflammatory 
phenotype that has a supportive rather than a harmful effect on neuronal cells.
To reveal the underlying mechanisms of CNS disorders, the complex cellular interactions between glial and 
neuronal cells should be investigated in more detail. Microfluidic technology can provide in vitro research tools 
that go beyond conventional cell culture methods with the aim of better modeling in vivo environments31,32. Here, 
our microfluidic platform was developed to co-culture the two cell types in a compartmentalized, controlled 
manner to specifically study axonal interactions with glial cells. Co-culture of human neurons and astrocytes 
was successful in the platform, which allowed direct contact between astrocyte processes and axons. Moreover, 
fluidic isolation enabled targeted stimulation of astrocytes in their compartment while also permitting humoral 
effects on neuronal axons extending into the axonal compartment. Activation of astrocytes with IL-1β and TNF-α 
was reproduced selectively in the microfluidic platform, and the inflammatory niche promoted axonal growth, 
further suggesting neurosupportive characteristics. This interpretation is supported by a recent report in which 
IL-1β mediated a potentially neuroprotective astrocyte phenotype expressing axonal permissive transcripts57. A 
microfluidic platform has been previously used for analysis of the neuroinflammatory mechanisms of astrocytes 
and microglia in the neurotoxic environment of Alzheimer’s disease26. Our results present a unique microflu-
idic device designed for studying the interactions of axons and glial cells and further validate the suitability of 
microfluidic platforms as tools for studying the complex interplay among multiple cell types in the contexts of 
neuroinflammation and neurodegeneration.
In conclusion, our results suggest that extended co-stimulation with IL-1β and TNF-α produces a reactive 
astrocyte phenotype with a broad inflammatory secretion profile that displays neurosupportive characteristics 
with regard to neuronal viability, functionality and axonal growth. The mechanism behind the neurosupportive 
effects need to be clarified in the future studies. Furthermore, an in vitro model combining human cells and 
microfluidic technology was developed, and the usefulness of the proposed novel microfluidic platform for inves-
tigation of neuron-astrocyte interactions in an inflammatory environment was demonstrated. Advancing the field 
of in vitro modeling and creating tools for studying intricate cellular interactions in neurological disorders will 
promote the discovery of novel neuroprotective therapeutic targets in the future.
Methods
Human pluripotent stem cells and differentiation of neurons and astrocytes. The hPSC lines 
Regea 08/02358 and 10212.EURCCs59 used in this study were derived at the Faculty of Medicine and Health 
Technology (MET), Tampere University, Finland. MET has approval from the Finnish Medicines Agency 
(FIMEA) for research utilizing human embryos (Dnro 1426/32/300/05) and has received supportive statements 
from the regional ethics committee of Pirkanmaa Hospital District for the derivation, culture, and differentiation 
of hESCs (R05116) and hiPSCs (R08070). An informed consent was obtained from all subjects who provided 
cell samples. All methods were carried out in accordance with relevant guidelines and regulations. The hiPSC 
line 10212.EURCCs was derived from human skin fibroblasts using Sendai virus technology60. The hPSC lines 
were expanded in feeder-free culture as described earlier61. The in-house-produced neurons were differentiated 
according to the methods in a previous publication62, with some modifications (details in the Supplementary 
methods).
Commercial hiPSC-derived neurons (ax0018) and astrocyte progenitors (ax0083) from healthy donors were 
cultured according to the manufacturer’s protocol (both from Axol Bioscience Inc., UK). The astrocyte progen-
itors were differentiated for 24 days in culture and then treated for 7 days with 10 ng/ml human recombinant 
TNF-α and 10 ng/ml human recombinant IL-1β (PeproTech Inc.). Samples for astrocyte characterization were 
collected during the treatment at the 0 h, 24 h, 72 h and 7 day time points (Fig. 2a).
RNA isolation and quantitative PCR. RNA was isolated from astrocytes with a NucleoSpin RNA kit 
(Macherey-Nagel). The concentration and purity of RNA were quantified with a NanoDrop 1000 (Thermo Fisher 
Scientific). RNA was converted to cDNA using a High Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific). The expression levels of CCL5, CXCL8, GFAP, LCN2, C3, GFAP, VIM, S100B, IL1R, IL1RAP, 
TNFRSF1A and TNFRSF1B (Supplementary Table 3) were analyzed with TaqMan assays using an ABI Prism 7300 
real-time PCR system (Thermo Fisher Scientific). The data were analyzed using the delta Ct method using GUSB 
and GAPDH as endogenous controls.
Immunocytochemical staining. Immunocytochemical staining was performed according to the methods 
in a previous publication63. The used primary and secondary antibodies are listed in the Supplementary Table 4. 
Images were acquired with an Olympus IX51 microscope equipped with an Olympus DP30BW camera (Olympus 
Corporation, Germany) or an LSM780 laser-scanning confocal microscope equipped with a Quasar spectral 
GaAsP detector (all from Carl Zeiss, Germany). CellProfiler64 and CellProfiler Analyst65 software was used to 
perform image analysis. For evaluation of astrocyte morphology, the FormFactor module of CellProfiler software 
was used to calculate circularity index according to the area and perimeter metrics of each cell. Circularity index 
was calculated as 4*π*Area/Perimeter2, with a value of 1 describing a perfectly circular object.
Glutamate uptake. Glutamate uptake by cultured cells was analyzed with a glutamate assay kit (Abcam). 
The cells were washed with PBS and with 0.1% BSA in PBS for 30 min + 37 °C. The cells were then incubated with 
100 μM glutamate in PBS for 1 h + 37 °C. Finally, the cells were washed with PBS and lysed with assay buffer. The 
concentration of glutamate in the cell lysate was analyzed according to the manufacturer’s protocol.
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Cell proliferation assay. A CyQUANT Cell Proliferation Assay (Thermo Fisher Scientific) was used to ana-
lyze the DNA amounts in cultured cells according to the manufacturer’s protocol. Fluorescence was measured at 
520 nm (Wallac Victor 1420, PerkinElmer).
Cell viability and apoptosis assay. Cell viability and caspase-3/7 activation were detected in cultured 
cells with an ApoTox-Glo Triplex Assay (Promega). For positive controls, cells were treated with 1.25 µM stau-
rosporine and 25 µM ionomycin (both from Sigma) for 6 h. Fluorescence was measured at 505 nm and 520 nm 
for viability and cytotoxicity, respectively. Luminescence was measured to detect apoptosis (Wallac Victor 1420).
Collection of astrocyte conditioned medium. Astrocyte conditioned medium (ACM) from 
cytokine-treated and control astrocytes was collected at the 9-day time point. First, astrocytes were treated for 
7 days with the cytokines IL-1β and TNF-α; thereafter, the cells were washed with PBS, and fresh medium was 
added to the cells. At day 9, the medium was harvested and centrifuged at 400 × g for 5 min at RT, and the super-
natant was collected and stored at -80 °C until use. Neuronal cells (in-house-derived hESC line Regea 08/023) 
were exposed to ACM or control medium for 24 h (MEA analysis) or 48 h (viability assay) before analysis. The 
experiments with ACM also included a control group; the control medium was prepared similarly to the ACM 
but without astrocytes.
Cytokine array and ELISA. Protein secretion (see the list of analytes in Supplementary Table 1) into the 
astrocyte culture medium was measured using a Proteome Profiler Antibody Array (Human XL Cytokine Array 
Kit, ARY022B, R&D Systems) according to the manufacturer’s protocol. The membranes were imaged with a 
ChemiDoc imaging system (Bio-Rad), and the intensity of the spots was quantified with Image Lab software 
(Bio-Rad).
The levels of IL-6 in the medium were measured with a human IL-6 uncoated ELISA kit (#88-7066-22, 
Thermo Fisher Scientific) according to the manufacturer’s protocol. The absorbance was measured at 450 nm 
(Wallac Victor 1420).
Viability staining. A viability/cytotoxicity kit for mammalian cells (Thermo Fisher Scientific) was used to 
evaluate the viability of cells after ACM treatment and culture in the microfluidic platform. The cultures were 
incubated for 30 min to 1 h at 37 °C with green-fluorescent calcein-AM (0.5 µM) for detection of live cells and with 
red-fluorescent ethidium homodimer-1 (0.5 µM) for detection of dead cells. The samples were imaged immedi-
ately with an Olympus IX51 microscope equipped with an Olympus DP30BW camera (Olympus Corporation) 
and an LSM780 laser-scanning confocal microscope equipped with a Quasar spectral GaAsP detector (Carl 
Zeiss).
Microelectrode array measurements. Neuronal network activity was recorded with an Axion Maestro 
system controlled by AxIS Software (Axion Biosystems, Atlanta, GA, USA) with 12.5 kHz sampling rate as 
described previously66. The hPSC-derived cortical neurons (in-house-derived hESC line Regea 08/023 or com-
mercial hiPSC-derived neurons, ax0018) were plated on CytoView MEA 48 plates with 16 electrodes per array. 
Recordings were obtained under a controlled temperature of 37 °C. Spontaneous activity development was exam-
ined once a week with 10-minute recordings. After five weeks, when synchronous network activity had developed, 
the experiments with astrocyte conditioned medium (ACM) were initiated. The responses to control medium, 
control ACM or reactive ACM were measured for 10 min immediately and at 1 h, 4 h and 24 h after application. 
Analysis methods for spike and burst detection are described in the Supplementary methods section.
Design of the microfluidics device. An in-house-developed microfluidics polydimethylsiloxane 
(PDMS) device (Patent: WO2015092141A1) was used (Fig. 6a, Supplementary Fig. S7). The device contains 
three separate cell compartments and an axonal compartment that are interconnected by microtunnels (Fig. 6b, 
Supplementary Fig. S7). There are two neuronal compartments (length = 4250 µm, width = 3000 µm) that are 
connected to the axonal compartment (length = 1000 µm, height = 100 µm, width = 100 µm) with three micro-
tunnels (length = 250 µm, height = 3 µm, width = 10 µm). The microtunnels allow the extension of axons but pre-
vent the migration of neuronal somas from the neuronal compartment into the axonal compartment (Fig. 6b,c). 
The flow-based astrocyte compartment is connected to the axonal compartment with seven microtunnels 
(length = 50 µm, height = 3.5 µm, width = 10 µm) (Supplementary Fig. S7). The fabrication of PDMS devices are 
described in the Supplementary methods.
Co-culture of neurons and astrocytes in the microfluidic platform. HiPSC-derived cortical neurons 
(10212.EURCCs) and commercial hiPSC-derived astrocytes (ax0083) were seeded into the neuronal compart-
ments and astrocyte compartment, respectively (see details on Supplementary methods). Three days after cell 
plating, 10 ng/ml IL-1β- and TNF-α-containing medium was added into the astrocyte compartment, and treat-
ment continued for 3 days. After cytokine treatment, the viability of cells was assessed with viability staining, and 
astrocyte-secreted inflammatory factors were analyzed in medium collected from the astrocyte compartment. To 
characterize the astrocytes and neurons in the co-cultures, immunofluorescence staining was performed. First, 
the microfluidics devices were separated manually from the coverslips, and then the cells were fixed with 4% 
PFA and stained according to an immunocytochemical protocol. To evaluate the influences of the astrocytes and 
cytokines on axonal growth, the following experimental groups were established: 1) a group in which neurons 
were seeded in the neuronal compartments (the Neu group), 2) a group in which neurons were seeded in the 
neuronal compartments and cytokine treatment was conducted via the astrocyte compartment (the Neu + IL-1β/
TNF-α group), 3) a group in which neurons and astrocytes were seeded in their compartments (the Neu + Ctrl 
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astro group), and 4) a group in which neurons and astrocytes were seeded in their compartments and cytokine 
treatment was conducted via the astrocyte compartment (the Neu + Reactive astro group). The cells in the devices 
were imaged with phase-contrast microscopy at baseline and at 24 h and 72 h after cytokine treatment. The indi-
vidual axons entering the axonal compartment were counted manually from the images at a distance of 80 µm 
from the axonal microtunnels (the white dotted line in Fig. 7d). The density of the axons in the axonal compart-
ment was evaluated by analyzing the area covered with calcein-AM-stained axons at 72 h after cytokine treatment. 
The analyzed area was a 0.033 mm2 (325 µm × 100 µm) region next to the axonal microtunnels (the white dotted 
line in Fig. 7f), and analysis was performed using CellProfiler software.
Statistical analysis. Statistical analysis of Gaussian-distributed data was performed with independent-sample 
T-tests. If the data followed a non-Gaussian distribution, the nonparametric Mann-Whitney U-test was used. 
Bonferroni correction was used for multiple comparisons.
The MEA data followed a non-Gaussian distribution; therefore, nonparametric tests were selected. To study 
changes in activity within treatment groups over time, the Friedman test for related samples was performed fol-
lowed by the Wilcoxon signed-rank test to compare two related samples. To study differences between groups, 
delta values were calculated (by subtracting the baseline values from the values obtained immediately (acute), 1 h, 
4 h, or 24 h after treatment), and Mann-Whitney U-tests were performed.
A p-value < 0.05 was considered to indicate significance. Statistical significance is denoted as * p < 0.05, ** 
p < 0.01, and *** p < 0.001. All statistical tests were performed with SPSS Statistics software (version 25.0).
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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